Amgen
Is Amgen the Debt-Driven King of Return on Equity?
Can Amgen's stunning ROE of 53% keep leading the pack despite its high debt? Let’s dive into the numbers!
See moreCan Amgen's stunning ROE of 53% keep leading the pack despite its high debt? Let’s dive into the numbers!
See moreFrom defense to biotech, Austin’s new startups are shaking up industries. Here’s why you should keep an eye on them!
See more